Hypertriglyceridemia

Inversago Pharma Presents Data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress

Retrieved on: 
목요일, 5월 19, 2022
Health, Diabetes, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Prader–Willi syndrome, Metabolic disorder, Disease, Medical research, T1D, NASH, Lipid, Idiopathic pulmonary fibrosis, Pancreas, National Institute, Patient, Nephrology, Kidney disease, Gene expression, Fatty liver disease, Muscle, Obesity, Liver, Human, CB1, ERA, Progressive, Mouse, DN, STZ, Fibrosis, Kidney, Congress, ACR, Diabetic nephropathy, European Renal Association – European Dialysis and Transplant Association, PWS, IPF, HTG, Pharmaceutical industry, Diabetes, Hypertriglyceridemia, Albuminuria

These data show that INV-202, the companys lead peripheral CB1 blocker, reduced renal injury in a murine model of Streptozotocin (STZ)-induced Diabetes.

Key Points: 
  • These data show that INV-202, the companys lead peripheral CB1 blocker, reduced renal injury in a murine model of Streptozotocin (STZ)-induced Diabetes.
  • In particular, there was a marked, dose-dependent reduction in albuminuria in this model of diabetes and associated kidney injury.
  • The study showed that treatment with INV-202 reduced the progression of nephropathy in STZ-induced diabetic mice.
  • INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions, including Diabetic Nephropathy.

Inversago Pharma Appoints Glenn S. Vraniak as Chief Financial Officer

Retrieved on: 
화요일, 5월 17, 2022
Biotechnology, Diabetes, Pharmaceutical, Health, Prader–Willi syndrome, T1D, NASH, Doctor of Philosophy, Idiopathic pulmonary fibrosis, Patient, GE Capital, Fatty liver disease, Obesity, Electronic, CB1, ElectroCore, Progressive, DN, Industry, Technology, Organization, Diabetic nephropathy, Management development, IPO, PWS, IPF, CFO, HTG, Pharmaceutical industry, Management, Nasdaq, Hypertriglyceridemia

Inversago Pharma Inc. (Inversago), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces the appointment of Glenn S. Vraniak to the position of Chief Financial Officer (CFO), effective immediately.

Key Points: 
  • Inversago Pharma Inc. (Inversago), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces the appointment of Glenn S. Vraniak to the position of Chief Financial Officer (CFO), effective immediately.
  • Mr. Vraniaks career spans more than 20 years of financial and commercial experience in the life sciences industry.
  • Before joining Inversago, Mr. Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company and led the company through a successful IPO on Nasdaq in February 2021, and successfully raised follow-on capital later that same year.
  • Prior to that, Mr. Vraniak served as the Chief Financial Officer of electroCore, Inc. and was a key member of the management team that led the company through a successful IPO on Nasdaq in June 2018.

89bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
수요일, 5월 11, 2022
Population, R, Private Securities Litigation Reform Act, Research, NASH, Hypertriglyceridemia, Disclosure, Patient, Investment, FGF21, Health, The O.C., Liver, Half-life, MPH, COVID-19, Trial of the century, Fatty liver disease, SAN, Triglyceride, Research and development, Probability, Safe harbor, Adoption, LinkedIn, Administration, Harvard Medical School, Atherosclerosis, SEC, GLOBE, Pharmaceutical industry, Medical imaging, Airline, G&A, Brigham, MD

SAN FRANCISCO, May 11, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the quarter ended March 31, 2022.

Key Points: 
  • Topline data for the Phase 2 ENTRIGUE trial of pegozafermin in SHTG patients expected in the second quarter of 2022.
  • As of March 31, 2022, 89bio had cash, cash equivalents, and short-term investments of $126.1 million.
  • 89bio claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.
  • 89bio expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Severe Hypertriglyceridemia (SHTG) Epidemiology Forecasts, 2032 - ResearchAndMarkets.com

Retrieved on: 
수요일, 5월 4, 2022
Health, Other Health, United Kingdom, Population, Epidemiology, Hypertriglyceridemia, Disease, CAGR, Medical imaging, Lithium, Medical device

The "Severe Hypertriglyceridemia (SHTG) - Epidemiology Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Severe Hypertriglyceridemia (SHTG) - Epidemiology Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This 'Severe Hypertriglyceridemia- Epidemiology Forecast-2032' report delivers an in-depth understanding of the Severe Hypertriglyceridemia, historical and forecasted epidemiology as well as the Severe Hypertriglyceridemia trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of hypertriglyceridemia, diagnosed prevalent cases of hypertriglyceridemia, severity-specific diagnosed prevalent cases of hypertriglyceridemia, and etiology-specific diagnosed prevalent cases of severe hypertriglyceridemia scenario of Severe Hypertriglyceridemia in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
  • The report provides the segmentation of the disease epidemiology for 7MM, a total number of prevalent cases of hypertriglyceridemia, diagnosed prevalent cases of hypertriglyceridemia, severity-specific diagnosed prevalent cases of hypertriglyceridemia, and etiology-specific diagnosed prevalent cases of severe hypertriglyceridemia

89bio to Participate in Upcoming Investor Conferences

Retrieved on: 
화요일, 5월 3, 2022
NASH, Fatty liver disease, Liver, Hypertriglyceridemia, FGF21, SAN, Patient, Half-life, GLOBE, LinkedIn, Pharmaceutical industry

SAN FRANCISCO, May 03, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Companys Management will participate in the following upcoming investor conferences in May:

Key Points: 
  • SAN FRANCISCO, May 03, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Companys Management will participate in the following upcoming investor conferences in May:
    89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options.
  • The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).
  • Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life.
  • The company is headquartered in San Francisco with operations in Herzliya, Israel.

HighTide Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus

Retrieved on: 
목요일, 4월 28, 2022
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Adult, A1C, CEO, Fatty liver disease, Roy Taylor (scientist), Association, Patient, Glycated hemoglobin, Hypertriglyceridemia, Incidence, Therapy, Cirrhosis, Cardiovascular disease, HighTide, Liver, Prevalence, Primary sclerosing cholangitis, Primary biliary cholangitis, Insulin resistance, Hepatocellular carcinoma, Trial of the century, NASH, Risk, NAFLD, Population, Safety, Pharmaceutical industry, T2DM

HighTide Therapeutics, Inc. (HighTide), a globally integrated clinical-stage biotechnology company developing drugs with multi-functional biological actions to address the complex pathophysiology of metabolic and digestive diseases, announced that the first patient was dosed in a phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a globally integrated clinical-stage biotechnology company developing drugs with multi-functional biological actions to address the complex pathophysiology of metabolic and digestive diseases, announced that the first patient was dosed in a phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.
  • T2DM and NAFLD remain the most common chronic diseases worldwide with rapidly increasing prevalence and incidence.
  • Given the strong association and overlapping pathophysiology, there is a sizable population of patients with comorbid T2DM and NAFLD.
  • The complex pathophysiology of T2DM and NAFLD requires the engagement of multiple mechanistic pathways to optimize pharmacological intervention.

Inversago Pharma to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference to Be Held on May 2-3, 2022 in Toronto, ON

Retrieved on: 
월요일, 4월 11, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Obesity, CB1, Diabetic nephropathy, DN, Patient, Idiopathic pulmonary fibrosis, Progressive, T1D, Doctor of Philosophy, Conference, HTG, IPF, NASH, PWS, Prader–Willi syndrome, Fatty liver disease, Pharmaceutical industry, Hypertriglyceridemia

Inversago Pharma Inc. (Inversago), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announced that Franois Ravenelle, PhD, Chief Executive Officer, will be presenting at the Bloom Burton & Co. Healthcare Investor Conference.

Key Points: 
  • Inversago Pharma Inc. (Inversago), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announced that Franois Ravenelle, PhD, Chief Executive Officer, will be presenting at the Bloom Burton & Co. Healthcare Investor Conference.
  • Details are as follows:
    1-on-1 Meetings: Professional investors will have the opportunity to request 1-on-1 meetings with private and public companies, including Inversago Pharma.
  • The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector.
  • Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

Kyttaro Announces Worldwide Exclusive Licensing Agreement With Lilly for Antibody Therapeutic Program

Retrieved on: 
월요일, 4월 11, 2022
Consulting, Biotechnology, Banking, Technology, Professional Services, Health, Public Relations, Investor Relations, Communications, Other Technology, Insurance, Finance, Lipoprotein lipase, Risk, Cardiovascular disease, Population, Therapy, Acute pancreatitis, Triglyceride, Moyamoya disease, Death, LDL, Adult, Cambridge Science Festival, ANGPTL8, CSC, TGS, Research, Incidence, Hypercholesterolemia, LPL, HTG, Eli Lilly and Company, Union, Protein, Hypertriglyceridemia, Patient, Disease, Lilly, Antibody, Pharmaceutical industry, Kendall Square, ANGPTL3

Kyttaro announces that it has entered into an agreement for the worldwide exclusive license of an anti-angiopoietin-like (ANGPTL) 3/8 monoclonal antibody program developed by Eli Lilly and Company (Lilly) for potential treatment of atherosclerotic cardiovascular disease (ASCVD) and linked dyslipidemias: hypertriglyceridemia and hypercholesterolemia.

Key Points: 
  • Kyttaro announces that it has entered into an agreement for the worldwide exclusive license of an anti-angiopoietin-like (ANGPTL) 3/8 monoclonal antibody program developed by Eli Lilly and Company (Lilly) for potential treatment of atherosclerotic cardiovascular disease (ASCVD) and linked dyslipidemias: hypertriglyceridemia and hypercholesterolemia.
  • LPL hydrolyzes circulating triglycerides in the bloodstream, which is the primary mechanism by which triglyceride-rich lipoproteins are cleared from the circulation.
  • As such, the ANGPTL3/8 complexs inhibition of LPL causes increased levels of triglyceride-rich lipoproteins in the bloodstream and has negative implications for the development of ASCVD.
  • I would like to thank Lilly for the opportunity and welcome their company as an important shareholder in Kyttaro and as a valued partner.

89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
목요일, 3월 24, 2022
Administration, Private Securities Litigation Reform Act, Histology, Risk, Adiponectin, Lipid, LinkedIn, Fatty liver disease, Investment, Triglyceride, Trial of the century, The O.C., Growth, Liver, SEC, FAST, Half-life, Health, Teva Pharmaceuticals, MD, NASH, Safe harbor, Disclosure, COVID-19, NAFLD, Diabetes, GLOBE, Fibrosis, R, SAN, NAS, Annual report, Research and development, FGF21, Hypertriglyceridemia, Patient, Pharmaceutical industry, Medical imaging, Medical device, Fine chemical, G&A

SAN FRANCISCO, March 24, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the quarter and full year ended December 31, 2021.

Key Points: 
  • These data increase our confidence in the potential of pegozafermin to show a strong beneficial effect in our ongoing and future NASH trials.
  • As of December 31, 2021, 89bio had cash, cash equivalents, and short-term investments totaling $150.7 million compared to $204.7 million as of December 31, 2020.
  • 89bio claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.
  • 89bio expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

HighTide Therapeutics Appoints Myleen Leoncavallo as SVP Regulatory Affairs and Quality Assurance

Retrieved on: 
목요일, 3월 31, 2022
Biotechnology, General Health, Pharmaceutical, Health, Drug development, BioMarin Pharmaceutical, Therapy, University, Primary biliary cholangitis, Degenerative disease, Master of Science, Institute of Liver and Biliary Sciences, Regulatory affairs, Quality assurance, Cholestasis, Primary sclerosing cholangitis, Pregnancy, Biliary atresia, Medicinal chemistry, University of California, San Diego, HighTide, Cholestatic pruritus, Senior, Cell biology, T2DM, Alagille syndrome, Clinical trial, Hypertriglyceridemia, Patient, Pharmaceutical industry, Biochemistry, Science, Spiroplasma mirum

HighTide Therapeutics, Inc. (HighTide), a global, clinical-stage biopharmaceutical company leading the discovery and development of multi-functional drugs with synergistic effects to treat metabolic and digestive diseases, today announced the appointment of Myleen Leoncavallo as Senior Vice President of Regulatory Affairs and Quality Assurance.

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a global, clinical-stage biopharmaceutical company leading the discovery and development of multi-functional drugs with synergistic effects to treat metabolic and digestive diseases, today announced the appointment of Myleen Leoncavallo as Senior Vice President of Regulatory Affairs and Quality Assurance.
  • Mrs. Leoncavallo will report to Dr. Leigh MacConell, Chief Development Officer of HighTide.
  • We are very pleased to welcome Myleen to HighTide, said Liping Liu, Ph.D., Chief Executive Officer of HighTide.
  • Prior to Mirum, Mrs. Leoncavallo served in several senior regulatory affairs roles, including positions at Ultragenyx Pharmaceuticals and BioMarin Pharmaceuticals, biopharmaceutical companies focused on rare diseases.